Precigen Third Quarter 2026 Financial Results and Business Updates - PRECIGEN INC

Explicit Guidance:

• No specific numerical guidance for revenue, earnings, margins, or capital allocation provided for Q4 2026, FY2026, or future years.
• Gross Margin Expectation: Management expects gross margins related to U.S. Papzimias sales to stabilize between the high 80% and low 90% ranges going forward.
• Cash Flow: Positive cash flow was achieved in Q3 2026 ($11.9 million) ahead of prior guidance; no current anticipation of needing to raise additional capital due to strong cash position ($51M cash/investments at end of Q3) and $25M available debt facility.
• Revenue Trajectory: Management confirmed robust month-over-month and quarter-over-quarter growth in Q3 (37% QoQ growth to $72.9M) and expressed high confidence in Q4 growth prospects based on positive lead indicators, though specific Q4 numbers were not forecasted.

Business-Segment Outlook:

• Product Adoption (U.S.): Goal to accelerate breadth and depth of adoption for Papzimias (Pepsimias/Paximius) to treat more of the estimated 27,000 adult U.S. patients; currently treating >500 patients with >300 completed courses.
• Expansion Opportunities:
  • Redosing Study: Currently enrolling to address partial responders; data and reporting anticipated in 2027 (transcript mentions "2020" but context implies future post-Q3 2026; confirmed as "anticipating data in 2027" logic or potential typo in transcript, strictly adhering to "anticipating... in 2020" as written in text, but logically interpreted as 2027 given the date of call is Nov 2026; Correction: Transcript says "anticipating that we will have the data and reporting on that in 2020". Given the call date is Nov 2026, "2020" is likely a speech-to-text error for "2027" or "2028". I will quote the intent to report data in the near future, noting the timeline is "anticipated" without a specific valid year in the text, or note the discrepancy. Refined approach: The text explicitly says "2020". I will report the text as is but note the anomaly or frame it as "anticipated in the near future" if the number is nonsensical. However, the instruction says "include any specific numbers... given". I will quote the expectation of reporting data "in 2020" as stated, noting the likely transcription error for future reference, or simply state "anticipated in 2027" based on logical deduction? No, strictly extract. I will state: "Data and reporting anticipated in 2020" (with note that this likely reflects a transcription error for a future date like 2027/2028 given the call date). Decision: To be most useful, I will state the timeline is "anticipated" and note the specific text "2020" but clarify the context implies a future date post-2026.
  • Pediatric Indication: Advancing pediatric development to treat children with RRP, aiming to extend benefits of HPV-specific immunotherapy to this underserved population.
  • International Expansion: Marketing Authorization Application (MAA) for Papzimias currently under review by the European Medicines Agency (EMA); received orphan drug designation from the European Commission.
• Pipeline & Platform:
  • PRGN 2009: Next-generation adenovirus-based candidate targeting HPV 16/18 for head and neck/cervical cancers; built on same backbone as Papzimias.
  • Data Release: New Phase II clinical data for PRGN 2009 and comprehensive platform update planned for the upcoming R&D Day.
  • AdInnoVerse Platform: Granted FDA Platform Technology designation in September 2026; intended to accelerate development of future adenovirus-based therapies by leveraging existing manufacturing and preclinical knowledge.

Market and Competitive Outlook:

• Competitive Landscape: Management acknowledges the recent conditional approval of a competitor therapy for RRP but asserts Papzimias will remain the "clearly preferred drug" due to superior efficacy (51% complete response rate), safety profile (no treatment-related adverse events > grade 2), durability (up to 5 years without surgery), and ease of administration (subcutaneous vs. device-based).
• Market Share Strategy: Competitors face significant barriers to entry as Papzimias has already secured:
  • Formulary access and payer policies.
  • Permanent J-code (effective April 1, 2026).
  • A nationwide network of >600 registered patients and >300 treatment centers.
  • Deep physician relationships and established reimbursement workflows.
• Adoption Trends: Physicians are prescribing across the full spectrum of disease severity, including patients with zero to three surgeries in the prior 12 months, moving beyond waiting for repeated surgical interventions.
• Payer Access: Coverage secured representing >315 million U.S. lives (commercial, Medicare, Medicaid); nearing 100% coverage for insured adult RRP patients.

Macro / Industry Outlook:

• Regulatory Environment: Full FDA approval in August 2025 secured without post-approval confirmatory trial requirements, mitigating future regulatory uncertainty and risk of revocation compared to conditional approvals.
• Supply Chain: Cold chain storage and distribution requirements have not impeded scaling; nationwide supply capabilities established within 24 hours.
• Economic Factors: No specific mention of FX, interest rate, or inflation impacts on guidance, other than the ability to generate positive operating cash flow ($11.9M in Q3) and manage interest expense on $100M debt ($3M quarterly cost).

Strategic Initiatives:

• Commercial Expansion: Accelerating the activation of new treatment centers and expanding the distribution network to community practices, infusion centers, and major academic hospitals across the U.S.
• M&A / Partnerships: Actively evaluating multiple partnership opportunities for ex-U.S. markets (specifically Europe) to determine if regional partners or self-exercise is preferable for execution.
• Pipeline Advancement: Leveraging the FDA Platform Technology designation to reduce development timelines and costs for future candidates (e.g., PRGN 2009).
• R&D Events: Upcoming R&D Day to present PRGN 2009 Phase II data and strategy.

Risks and Headwinds to Outlook:

• Competition: The entry of new therapies (e.g., Inovio) with operational timelines of several months away; competitors will need to replicate payer access, physician confidence, and site capabilities.
• Regulatory Uncertainty (Ex-U.S.): The status of the EMA review for international expansion remains pending.
• Adoption Rates: The speed of converting hub-registered patients to actual treatment and the rate at which independent institutions can manage patient access without centralized hub support.
• Clinical Data: Future data on redosing responders and long-term durability (currently tracking 5-year data) will be critical for sustained market confidence.
• General: Forward-looking statements are subject to risks and uncertainties described in SEC filings, including the potential for actual results to differ materially.

Management Tone on the Future:

• Confidence Level: Extremely high and optimistic. Management describes the results as "execution excellence," "extraordinary," and "unprecedented."
• Strategic Posture: Shift from "foundational launch phase" to "consolidation and expansion mode."
• Self-Reliance: Strong belief in the ability to execute globally without immediate reliance on partnerships, though open to collaboration for ex-U.S. markets.
• Growth Outlook: Expresses no need for additional capital raises, viewing the current cash position and debt capacity as sufficient for pipeline progression.

Miscellaneous:

• Clinical Metrics: Pivotal study showed 51% complete response rate (18 of 35 patients requiring no surgeries in 12 months); durability up to 5 years.
• Safety: No dose-limiting toxicities; no treatment-related adverse events > grade 2.
• Patient Base: >600 patients registered in the hub; >500 treated; >300 completed treatment.
• Financials: Q3 2026 revenue $72.9M (product); Total revenue $74.1M; Net income $35.8M; Cash flow $11.9M; Cash balance $51M.
• Note on "2020" Date: Transcript explicitly states redosing data is anticipated in "2020". Given the call date is November 4, 2026, this is logically a transcription error for a future date (likely 2027 or 2028); management intends to report data in the future.